Está en la página 1de 1

Recovery timesafter shortterm intravenous dexmedetomidine/propofol sedation by intravenous atipamezole antagonist inBeagledogs. Tiemposderecuperacindespusdelasedacindecortaduracincon dexmedetomidina/propofol intravenososeguidodeantagonistaatipamezol intravenosoenperrosBeagle.

J R Lima1,M. J.R. M GarcaLindo 1, M.F. M F MartnCancho 1,D. D Celdrn 1, M.S.CarrascoJimnez2,F.M.SnchezMargallo 1.


1 Jess Usn Minimally Invasive Surgery Centre. http://www.ccmijesususon.com Carretera N-521, km. 41.8 10071 Cceres, Spain 2 Professor of Anaesthesiology, Medicine School, University of Cdiz, Spain.
28 perros Beagle sanos, hembras (peso

Introduction
The aim of present study was to assess recovery times after short-term intravenous dexmedetomidine/propofol dogs for non-surgical sedation dental by intravenous atipamezole antagonist in Beagle follow-up procedures 1. El objetivo de este estudio fue valorar los tiempos de recuperacin despus de la sedacin de corta duracin con dexmedetomidina/propofol, para procedimientos no quirrgicos de revisin dental, seguido de antagonista atipamezol intravenoso en perros Beagle 1.

13 91 9 kg, 13.91.9 kg edad 1.5-2 1 5-2 aos) recibieron va intravenosa dexmedetomidina 0.02 mg kg-1 (Dexdomitor; Orion Pharma, Espoo, Finland) y propofol sedacin 1 y mg kg-1 (PropoVet; del Abbott de Laboratories, Queenborough, UK). Al final de la comienzo se periodo recuperacin, administr atipamezol

Results
The mean times of sedation (in minutes) were statistically significant between them (table 1). There were no complications or over-sedation There were effects not during recovery. differences statistical

between the times (in minutes): - to being able to stand-up; p; and 2- to being g able to walk (table 1). No adverse effects were observed clinical after effects the of administration of atipamezole, which effectively reversed all dexmedetomidine. Although recovery times from G4 seems shorter than G1 (p=0.176 for stand-up) and G2 (p=0.091 for able to walk), the times needed for standing and able to walk were similar in all groups, without significant statistical differences. Los entre tiempos los medios de sedacin 1). No (en hubo minutos) fueron estadsticamente significativos mismos (tabla complicaciones o efectos de sobresedacin durante la recuperacin. No hubo difrencias significativas en los tiempos (en minutos): - de estacin sobre los cuatro miembros; y de deambulacin (tabla 1). No se observaron efectos adversos despus de administrar atipamezol, el cual revirti todos los efectos clnicos de la dexmedetomidina. Aunque los tiempos de recuperacin de G4 parecen ms cortos que G1 (p=0.176 para la estacin) y G2 (p=0.091 para la deambulacin), los tiempos necesarios para la estacin y la deambulacin

intravenoso 0.2 mg kg-1 (Antisedan; Orion Pharma, Espoo, Finland). La variable de estudio fue el tiempo de sedacin desde la administracin de dexmedetomomidina/ propofol hasta su reversin con atipamezol, y los perros fueron asignados aleatoriamente a uno de los 4 grupos (n=7) siguientes: Grupo 1 (G1) sedacin de 2 a 3 minutos; Grupo 2 (G2) sedacin de 4 a 5 minutos; Grupo 3 (G3) sedacin de 6 a 8 minutos; y Grupo 4 (G4) sedacin de 9 a 12 minutos. Los tiempos de recuperacin desde la administracin de atipamezol hasta alcanzar la estacin sobre los miembros, y el inicio de la deambulacin, se registraron en todos los animales, a los que se les permiti recuperarse espontneamente. Se aplicaron ANOVA y test de Tukey, siendo considerada significativa p<0.05. Los resultados se expresan como media+SD.
Table 1. Mean times SD (in minutes) of sedation, to standup, and to be able to walk.

MaterialandMethods
Twenty eight healthy female Beagle dogs (weight 13.91.9 kg, aged 1.5-2 years old) received intravenous dexmedetomidine 0.02 mg kg-1 (Dexdomitor; Orion Pharma, Espoo, UK). Finland) plus propofol 1 mg kg-1 (PropoVet; Abbott Laboratories, Queenborough, Intravenous atipamezole 0.2 mg kg-1 (Antisedan; Orion Pharma, Espoo, Finland) was given at the end of sedation and starting the recovery period. The time of sedation, to from dexmedetomidine/propofol atipamezole

administration, was the study variable and the dogs were randomly assigned to 4 groups of 7 as follows: Group 1 (G1) from 2 to 3 minutes; G Group 2 (G2) (G ) from f 4 to 5 minutes; Group G 3 (G3) (G ) from 6 to 8 minutes; Group 4 (G4) from 9 to 12 minutes. Recovery times from atipamezole administration to being able to stand and walk were recorded in all animals, which were allowed to recover spontaneously. ANOVA and Tukey tests were performed with p<0.05 considered co s de ed s significant. g ca t The e results esu ts a are eg given e as mean+SD.
Dexdomitor, Antisedan and PropoVet are products marketed by ESTEVE, Barcelona, in Spain. Financial support of present study was provided by GOBEX, FEDER and ESTEVE funds.

* Significantly different (P < 0.05) to other groups.

fueron similares en todos los grupos, sin diferencias estadsticamente significativas entre los mismos.

References
1- Granholm M, McKusik BC, Westerholm FC, Aspegrn JC. Evaluation of the clinical efficacy and safety of intramuscular and intravenous doses of dexmedetomidine and medetomidine in dogs and their reversal with atipamezole. Vet Rec 2007; 160(26): 891-897..

Conclusions

The reversal effects of intravenous atipamezole provided safe and short recovery times after short-term intravenous dexmedetomidine/ propofol sedation in Beagle dogs. Los efectos reversores de atipamezol intravenoso proporcionaron una recuperacin segura y rpida despus de la sedacin intravenosa de corta duracin con dexmedetomidina/propofol en perros Beagle.